Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
Enbrel 50 mg solution for injection in pre-filled syringe, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab 0.5 mL Varioject Placebo, Enbrel 25 mg powder and solvent for solution for injection
Janssen-Cilag International N.V.
Chronic Plaque Psoriasis
1 trial -
Endoxifen, Identical placebo tablets of Endoxifen manufactured by Intas Pharmaceuticals Limited, India. The placebo tablets were manufactured using the same excipients and the manufacturing process of endoxifen tablets. Like endoxifen 8 mg tablets, the placebo tablets are green coloured, round shape, biconvex, enteric coated tablets plain on both sides. The placebo for Endoxifen Tablets 8 mg was manufactured following the same procedure as the drug product without using endoxifen citrate.
Lacuna Pharma Pty Ltd
Bipolar I Disorder
1 trial -
Enema transplant of fecal microbiota, Placebo Enema transplant of fecal microbiota
Pari Pharma GmbH
Adult patients with ulcerative colitis diagnosed for at least 3 months
1 trial -
Enhanced standard management
United Therapeutics Europe Ltd
Pacemaker Complication
1 trial -
Epinephrine HFA-MDI (E004)
Amphastar France Pharmaceuticals
Asthma
1 trial -
Eplontersen
IONIS PHARMACEUTICALS INC
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
1 trial -
Eplontersen
IONIS PHARMACEUTICALS INC
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
2 trials -
Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).
Lacuna Pharma Pty Ltd
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
Erenumab, Placebo for AMG 334
Amgen
Episodic Migraine
1 trial -
EscharEx, Placebo (Gel Vehicle), Amnion/Chorion Membrane Allograft
MediWound Germany GmbH
Venous leg ulcer
1 trial -
Eslicarbazepine acetate (BIA 2-093)
Bial Portela & Companhia S.A.
Partial Epilepsy in Children and Adolescents
1 trial -
Etanercept
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Rheumatoid Arthritis
1 trial -
Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg
NovoThirteen
sickle cell disease (SCD)
1 trial -
Etrasimod Arginine Blue Placebo, Etrasimod Arginine Blue, Etrasimod Arginine Blue
Lacuna Pharma Pty Ltd
Crohn's Disease
1 trial -
Etripamil
Milestone Pharmaceuticals
Paroxysmal Supraventricular Tachycardia
1 trial -
Etripamil NS
Milestone Pharmaceuticals
Paroxysmal Supraventricular Tachycardia
2 trials -
Etripamil NS 70 mg
Milestone Pharmaceuticals
Tachycardia, Supraventricular
1 trial -
Etripamil NS 70 mg
Milestone Pharmaceuticals
Paroxysmal Supraventricular Tachycardia
2 trials -
Everolimus
Jazz Pharmaceuticals Ireland Limited
Diffuse Intrinsic Pontine Glioma
1 trial -
Everolimus
Novartis Pharmaceuticals
Advanced NET of GI Origin
1 trial -
Everolimus-ratiopharmยฎ 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN
Stemline Therapeutics B.V.
patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.
1 trial -
Evolocumab
COLLEGIUM PHARMACEUTICAL, INC
Sars-CoV-2 Infection
1 trial -
Evorpacept (ALX148)
ALX ONCOLOGY HOLDINGS INC
Gastric Cancer
1 trial -
Exa-cel
Vertex Pharmaceuticals (Australia) Pty.
Sickle Cell Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources